| Literature DB >> 30060754 |
Paul Montgomery1, Sean Grant2, Evan Mayo-Wilson3, Geraldine Macdonald4, Susan Michie5, Sally Hopewell6, David Moher7.
Abstract
BACKGROUND: Randomised controlled trials (RCTs) are used to evaluate social and psychological interventions and inform policy decisions about them. Accurate, complete, and transparent reports of social and psychological intervention RCTs are essential for understanding their design, conduct, results, and the implications of the findings. However, the reporting of RCTs of social and psychological interventions remains suboptimal. The CONSORT Statement has improved the reporting of RCTs in biomedicine. A similar high-quality guideline is needed for the behavioural and social sciences. Our objective was to develop an official extension of the Consolidated Standards of Reporting Trials 2010 Statement (CONSORT 2010) for reporting RCTs of social and psychological interventions: CONSORT-SPI 2018.Entities:
Keywords: CONSORT; Randomised controlled trial; Reporting guideline; Reporting standards; Transparency
Mesh:
Year: 2018 PMID: 30060754 PMCID: PMC6066921 DOI: 10.1186/s13063-018-2733-1
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Fig. 1Flow of potential checklist items through CONSORT-SPI 2018 project
The CONSORT-SPI 2018 checklist
| Section | Item # | CONSORT 2010 | CONSORT-SPI 2018 |
|---|---|---|---|
| Title and abstract | |||
| 1a | Identification as a randomised trial in the title§ | ||
| 1b | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for Abstracts)§ | Refer to CONSORT extension for social and psychological intervention trial abstracts | |
| Introduction | |||
| Background and objectives | 2a | Scientific background and explanation of rationale§ | |
| 2b | Specific objectives or hypotheses§ | If pre-specified, how the intervention was hypothesised to work | |
| Methods | |||
| Trial design | 3a | Description of trial design (such as parallel, factorial), including allocation ratio§ | If the unit of random assignment is not the individual, please refer to CONSORT for Cluster Randomised Trials [ |
| 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | ||
| Participants | 4a | Eligibility criteria for participants§ | When applicable, eligibility criteria for settings and those delivering the interventions |
| 4b | Settings and locations where the data were collected | ||
| Interventions | 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered§ | |
| 5a | Extent to which interventions were actually delivered by providers and taken up by participants as planned | ||
| 5b | Where other informational materials about delivering the intervention can be accessed | ||
| 5c | When applicable, how intervention providers were assigned to each group | ||
| Outcomes | 6a | Completely defined pre-specified outcomes, including how and when they were assessed§ | |
| 6b | Any changes to trial outcomes after the trial commenced, with reasons | ||
| Sample size | 7a | How sample size was determined§ | |
| 7b | When applicable, explanation of any interim analyses and stopping guidelines | ||
| Randomisation | |||
| Sequence generation | 8a | Method used to generate the random allocation sequence | |
| 8b | Type of randomisation; details of any restriction (such as blocking and block size)§ | ||
| Allocation concealment mechanism | 9 | Mechanism used to implement the random allocation sequence, describing any steps taken to conceal the sequence until interventions were assigned§ | |
| Implementation | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions§ | |
| Awareness of assignment | 11a | Who was aware of intervention assignment after allocation (for example, participants, providers, those assessing outcomes), and how any masking was done | |
| 11b | If relevant, description of the similarity of interventions | ||
| Analytical methods | 12a | Statistical methods used to compare group outcomes§ | How missing data were handled, with details of any imputation method |
| 12b | Methods for additional analyses, such as subgroup analyses, adjusted analyses, and process evaluations | ||
| Results | |||
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers randomly assigned, receiving the intended intervention, and analysed for the outcomes§ | Where possible, the number approached, screened, and eligible prior to random assignment, with reasons for non-enrolment |
| 13b | For each group, losses and exclusions after randomisation, together with reasons§ | ||
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up | |
| 14b | Why the trial ended or was stopped | ||
| Baseline data | 15 | A table showing baseline characteristics for each group§ | Include socioeconomic variables where applicable |
| Numbers analysed | 16 | For each group, number included in each analysis and whether the analysis was by original assigned groups§ | |
| Outcomes and estimation | 17a | For each outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)§ | Indicate availability of trial data |
| 17b | For binary outcomes, the presentation of both absolute and relative effect sizes is recommended | ||
| Ancillary analyses | 18 | Results of any other analyses performed, including subgroup analyses, adjusted analyses, and process evaluations, distinguishing pre-specified from exploratory | |
| Harms | 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for Harms) | |
| Discussion | |||
| Limitations | 20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | |
| Generalisability | 21 | Generalisability (external validity, applicability) of the trial findings§ | |
| Interpretation | 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | |
| Important information | |||
| Registration | 23 | Registration number and name of trial registry | |
| Protocol | 24 | Where the full trial protocol can be accessed, if available | |
| Declaration of interests | 25 | Sources of funding and other support; role of funders | Declaration of any other potential interests |
| Stakeholder involvement* | 26a | Any involvement of the intervention developer in the design, conduct, analysis, or reporting of the trial | |
| 26b | Other stakeholder involvement in trial design, conduct, or analyses | ||
| 26c | Incentives offered as part of the trial | ||
This table lists items from the CONSORT 2010 checklist (with some modifications for social and psychological intervention trials as described in Table 2) and additional items in the CONSORT-SPI 2018 extension. Empty rows in the ‘CONSORT-SPI 2018’ column indicate that there is no extension to the CONSORT 2010 item
*We strongly recommended that the CONSORT-SPI 2018 Explanation and Elaboration (E&E) document be reviewed when using the CONSORT-SPI 2018 checklist for important clarifications on each item
§An extension item for cluster trials exists for this CONSORT 2010 item
Noteworthy changes to CONSORT 2010 items in the CONSORT-SPI 2018 checklist
| • Item 6a. The distinction between ‘primary’ versus ‘secondary’ outcomes has been removed. |
Fig. 2The CONSORT-SPI 2018 flow diagram
Items to report in journal or conference abstracts for social and psychological intervention trials [39]
| Section | CONSORT abstract item | Relevant CONSORT-SPI item |
|---|---|---|
| Title | Identification of the study as randomised | |
| Authors | Contact details for the corresponding author | |
| Trial design | Description of the trial design (e.g. parallel, cluster, noninferiority) | If the unit of random assignment is not the individual, refer to CONSORT for Cluster Randomised Trials and report the items included in its extension for abstracts [ |
| Methods | ||
| Participants | Eligibility criteria for participants and the settings where the data were collected | When applicable, the eligibility criteria for the setting of the intervention delivery and the eligibility criteria for the persons who delivered the interventions |
| Interventions | Interventions intended for each group | |
| Objective | Specific objective or hypothesis | If pre-specified, how the intervention was hypothesised to work |
| Outcomes | Clearly defined primary outcome for this report | |
| Randomisation | How participants were allocated to interventions | |
| Awareness of assignment | Who was aware of intervention assignment after allocation (for example, participants, providers, those assessing outcomes), and how any masking was done | |
| Results | ||
| Number randomly assigned | Number randomised to each group | |
| Recruitment | Trial status | |
| Interventions | Extent to which interventions were actually delivered by providers and taken up by participants as planned | |
| Number analysed | Number analysed in each group | |
| Outcomes | For the primary outcome, a result for each group and the estimated effect size and its precision | |
| Harms | Important adverse events or side effects | |
| Conclusions | General interpretation of the results | |
| Trial registration | Registration number and name of trial register | |
| Funding | Source of funding | |
Items to report in the abstract for cluster randomised social and psychological intervention trials [33]
| Section | CONSORT Abstract item | Relevant CONSORT Cluster extension item |
|---|---|---|
| Title | Identification of the study as randomised | Identification of study as cluster randomised |
| Authors | Contact details for the corresponding author | |
| Trial design | Description of the trial design (e.g. parallel, cluster, noninferiority) | |
| Methods | ||
| Participants | Eligibility criteria for participants and the settings where the data were collected | Eligibility criteria for clusters |
| Interventions | Interventions intended for each group | |
| Objective | Specific objective or hypothesis | Whether objective or hypothesis pertains to the cluster level, the individual participant level, or both |
| Outcomes | Clearly defined primary outcome for this report | Whether the primary outcome pertains to the cluster level, the individual participant level, or both |
| Randomisation | How participants were allocated to interventions | How clusters were allocated to interventions |
| Awareness of assignment | Who was aware of intervention assignment after allocation (for example, participants, providers, those assessing outcomes), and how any masking was done | |
| Results | ||
| Number randomly assigned | Number of participants randomised to each group | Number of clusters randomised to each group |
| Recruitment | Trial status | |
| Number analysed | Number of participants analysed in each group | Number of clusters analysed in each group |
| Outcomes | For the primary outcome, a result for each group and the estimated effect size and its precision | Results at the cluster or individual level as applicable for each primary outcome |
| Harms | Important adverse events or side effects | |
| Conclusions | General interpretation of the results | |
| Trial registration | Registration number and name of trial register | |
| Funding | Source of funding | |
Items to report in the main text for cluster randomised social and psychological intervention trials [33]
| Section | Item # | Cluster extension item |
|---|---|---|
| Title | 1a | Identification as a cluster randomised trial in the title |
| Abstract | 1b | See Table |
| Introduction | ||
| Background and objectives | 2a | Rationale for using a cluster design |
| 2b | Whether objectives pertain to the cluster level, the individual participant level, or both | |
| Methods | ||
| Trial design | 3a | Definition of cluster and description of how the design features apply to the clusters |
| Participants | 4a | Eligibility criteria for clusters |
| Interventions | 5 | Whether interventions pertain to the cluster level, the individual participant level, or both |
| Outcomes | 6a | Whether outcome measures pertain to the cluster level, the individual participant level, or both |
| Sample size | 7a | Method of calculation, number of clusters(s) (and whether equal or unequal cluster sizes are assumed), cluster size, a coefficient of intracluster correlation (ICC or |
| Randomisation | ||
| Sequence generation | 8b | Details of stratification or matching if used |
| Allocation concealment mechanism | 9 | Specification that allocation was based on clusters rather than individuals and whether allocation concealment (if any) was at the cluster level, the individual participant level, or both |
| Implementation | 10a | Who generated the random allocation sequence, who enrolled clusters, and who assigned clusters to interventions |
| 10b | Mechanism by which individual participants were included in clusters for the purposes of the trial (such as complete enumeration, random sampling) | |
| 10c | From whom consent was sought (representatives of the cluster, individual cluster members, or both) and whether consent was sought before or after randomisation | |
| Analytical methods | 12a | How clustering was taken into account |
| Results | ||
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers of clusters that were randomly assigned, received the intended treatment, and were analysed for the primary outcome |
| 13b | For each group, losses and exclusions for both clusters and individual cluster members | |
| Baseline data | 15 | Baseline characteristics for the individual and cluster levels as applicable for each group |
| Numbers analysed | 16 | For each group, the number of clusters included in each analysis |
| Outcomes and estimation | 17a | Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or |
| Generalisability | 21 | Generalisability to clusters or individual participants (as relevant) |
The CONSORT-SPI Group
| Member | Organisation |
| Project Executive | |
| Sean Grant | RAND Corporation |
| Sally Hopewell | University of Oxford |
| Evan Mayo-Wilson | Johns Hopkins University |
| Susan Michie | University College London |
| David Moher | Ottawa Health Research Institute |
| Paul Montgomery | University of Birmingham |
| Geraldine Macdonald | University of Bristol |
| International Advisory Board | |
| Stakeholder Representatives of Behavioural and Social Science Disciplines | |
| J. Lawrence Aber | New York University |
| David Clark | University of Oxford |
| Manuel Eisner | University of Cambridge |
| Frances Gardner | University of Oxford |
| Steve Hollon | Vanderbilt University |
| Lawrence Sherman | University of Cambridge |
| James Thomas | UCL Institute of Education |
| Elizabeth Waters (deceased) | University of Melbourne |
| Joanne Yaffe | University of Utah |
| Stakeholder Representatives of Intervention Research Methodologists | |
| Andrew Booth | University of Sheffield |
| Peter Craig | University of Glasgow |
| Larry Hedges | Northwestern University |
| Stakeholder Representatives of Journals | |
| Doug Altman |
|
| Mark W. Fraser |
|
| Spyros Konstantopoulos |
|
| Kenneth McLeroy |
|
| Arthur Nezu |
|
| Edmund Sonuga-Barke |
|
| Gary VandenBos |
|
| Robert West |
|
| Stakeholder Representatives of Research Funders | |
| Robert Kaplan | Office of Behavioural and Social Sciences Research |
| Peter Kaufmann | National Heart, Lung, and Blood Institute |
| Brian Mittman | Patient-Centered Outcomes Research Institute |